Role Of Sub-Tenon Autologous Platelet Rich Plasma Injections In The Treatment Of Rp Associated Cystoid Macular Edema: Interventional Case Series

Doi: 10.36351/pjo.v42i3.2246

Abstract

Purpose:  Retinitis pigmentosa (RP)is a progressive degenerative disease that may develop complications such as cystoid macular edema (CME), epiretinal membrane (ERM), and cataracts. Our study aims to use platelet-rich plasma (PRP) to resolve the cystic spaces at the macula by healing the tissue damage done by RP disease and lowering tissue compliance to limit fluid accumulation.

Study Design:  Interventional Case Series.

Place and Duration of Study:  Ibrahim Eye Centre, Lahore from December 2024 to March 2025.

Methods:  Seven patients (12 eyes) with retinitis pigmentosa–associated CME received three sessions of autologous sub-Tenon PRP injections at 3-week intervals. Baseline evaluation included best-corrected visual acuity (BCVA), fundoscopy, optical coherence tomography (OCT), and intraocular pressure (IOP), all of which were repeated before each session. Final analysis compared pre-treatment findings with those obtained three weeks after the last injection.

Results:  OCT demonstrated a statistically significant reduction in central foveal thickness (mean 289.50 ± 124.28 µm pre-treatment vs. 254.42 ± 111.67 µm post-treatment; p = 0.038). Visual outcomes showed improvement in 3 patients and stability in 4 patients, particularly in eyes with resolution of macular edema. No serious adverse events were observed; one patient developed transient IOP elevation.

Conclusion:  Sub-Tenon PRP is a safe and potentially effective option for reducing macular edema in RP. However, larger studies with longer follow-up are required to confirm efficacy, evaluate durability of response, and assess the risk of recurrence or progression.